HER2 testing in gastric cancer: An update

被引：201

作者：

Abrahao-Machado, Lucas Faria ^{[1
]}

Scapulatempo-Neto, Cristovam ^{[1
]}

机构：

[1] Barretos Canc Hosp, Dept Pathol, Rua Antenor Duarte Villela 1331, BR-14784400 Barretos, SP, Brazil

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2016年 / 22卷 / 19期

关键词：

Human epidermal growth factor receptor 2 testing; Gastric cancer; Immunohistochemistry; Scoring system; Trastuzumab; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; HELICOBACTER-PYLORI; SCORING SYSTEM; EXPRESSION; FISH; VALIDATION; PROGNOSIS; CARCINOMA; OVEREXPRESSION;

D O I：

10.3748/wjg.v22.i19.4619

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.

引用

页码：4619 / 4625

页数：7

共 50 条

[21] A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas
Woo, Chang Gok
Ho, Won Jin
Park, Young Soo
Park, Sook Ryun
Ryu, Min-Hee
Jung, Hwoon-Yong
Kang, Yoon-Koo
PATHOLOGY, 2017, 49 (01) : 38 - 43
[22] HER2 Testing and Targeted Therapy in Advanced Gastric Cancer
Hoehler, Thomas
Rueschoff, Josef
Ridwelski, Karsten
Moehler, Markus
ONKOLOGIE, 2010, 33 : 26 - 30
[23] Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
Warneke, V. S.
Behrens, H. -M.
Boeger, C.
Becker, T.
Lordick, F.
Ebert, M. P. A.
Roecken, C.
ANNALS OF ONCOLOGY, 2013, 24 (03) : 725 - 733
[24] Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis
Jiang, H.
Li, Q.
Yu, S.
Yu, Y.
Wang, Y.
Li, W.
Cui, Y.
Liu, T.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (02): : 197 - 203
[25] Her2 Amplification in Gastric Cancer Is a Rare Event Restricted to the Intestinal Phenotype
Cruz-Reyes, Carolina
Gamboa-Dominguez, Armando
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2013, 21 (03) : 240 - 246
[26] Low frequency of HER2 amplification and overexpression in early onset gastric cancer
Moelans, Cathy B.
Milne, Anya N.
Morsink, Folkert H.
Offerhaus, G. Johan A.
van Diest, Paul J.
CELLULAR ONCOLOGY, 2011, 34 (02) : 89 - 95
[27] Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
Kolbe, Katharina
Haffner, Ivonne
Schierle, Katrin
Maier, Dieter
Geier, Birgitta
Luber, Birgit
Blaeker, Hendrik
Wittekind, Christian
Lordick, Florian
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1319 - 1329
[28] Her2 testing in gastric cancer
Rueschoff, J.
Nagelmeier, I.
Baretton, G.
Dietel, M.
Hoefler, H.
Schildhaus, H. U.
Buettner, R.
Schlake, W.
Stoss, O.
Kreipe, H. H.
PATHOLOGE, 2010, 31 (03): : 208 - +
[29] HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India
Tewari, Mallika
Kumar, Akhileshwar
Mishra, R. R.
Kumar, Mohan
Shukla, Hari S.
INDIAN JOURNAL OF SURGERY, 2015, 77 : S447 - S451
[30] Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH
Kondo, Junya
Yoshino, Shigefumi
Iida, Michihisa
Takeda, Shigeru
Nakashima, Chiyo
Watanabe, Yusaku
Nishiyama, Mitsuo
Tokumitsu, Yukio
Shindo, Yoshitaro
Nishimura, Taku
Suzuki, Nobuaki
Hoshii, Yoshinobu
Itoh, Hiroshi
Nagano, Hiroaki
ANTICANCER RESEARCH, 2024, 44 (02) : 621 - 630

← 1 2 3 4 5 →